ACR-368 + Gemcitabine
Phase 2Recruiting 2 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Endometrial Adenocarcinoma
Conditions
Endometrial Adenocarcinoma
Trial Timeline
Aug 29, 2022 → Apr 30, 2027
NCT ID
NCT05548296About ACR-368 + Gemcitabine
ACR-368 + Gemcitabine is a phase 2 stage product being developed by Acrivon Therapeutics for Endometrial Adenocarcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05548296. Target conditions include Endometrial Adenocarcinoma.
What happened to similar drugs?
0 of 20 similar drugs in Endometrial Adenocarcinoma were approved
Approved (0) Terminated (0) Active (20)
Hype Score Breakdown
Clinical
12
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05548296 | Phase 2 | Recruiting |
Competing Products
20 competing products in Endometrial Adenocarcinoma